CoChat

Effect of Liraglutide on Arterial Inflammation Assessed as [ 18 F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Open access
Ripa, Rasmus S., Zobel, Emilie H., von Scholten, Bernt J., Jensen, Jacob K., Binderup, Tina, Diaz, Lars J., Curovic, Viktor R., Hansen, Tine W., Rossing, Peter, Kjaer, Andreas · 2021 · Circulation: Cardiovascular Imaging
Cited by 53

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background: The mechanism behind the cardiovascular protection observed with human GLP-1 RA (glucagon-like peptide-1 receptor agonists) in type 2 diabetes is unknown. We hypothesized that treatment with the GLP-1 RA liraglutide had a positive effect on vascular inflammation. Methods: LIRAFLAME (Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebocontrolled, double-blind, parallel clinical PET/CT trial) was a double-blind, randomized controlled trial performed at a single university hospital clinic in Denmark. Patients with type 2 diabetes were via computer-generated randomization list assigned (1:1) liraglutide up to 1.8 mg or placebo once daily for 26 weeks. The primary end point was change in vascular inflammation over 26 weeks assessed by [ 18 F]-fluorodeoxyglucose positron emission tomography/computed tomography. Analyses were based on intention-to-treat. Key secondary outcomes included change in other indices of atherosclerosis. Results: Between October 26, 2017, and August 16, 2019, 147 patients were screened and 102 were randomly assigned to liraglutide (n=51) or placebo (n=51) and 99 (97%) completed the trial. Change in the [ 18 F]-fluorodeoxyglucose positron emission tomography measure of vascular inflammation (active-segment target-to-background ratio) did not differ between treatment groups: change from baseline to 26 weeks was −0.04 (95% CI, −0.17 to 0.08) in the liraglutide group compared with −0.09 (−0.19 to 0.01) in the placebo group (mean difference, 0.05 [95% CI, −0.11 to 0.21], P =0.53). Secondary analyses restricted to [ 18 F]-fluorodeoxyglucose positron emission tomography of the carotid arteries as well as other indices of atherosclerosis confirmed the primary result. We performed an explorative analysis of interaction between treatment group and history of cardiovascular disease ( P =0.052). Conclusions: In this low to moderate risk population with type 2 diabetes, liraglutide did not change vascular inflammation assessed as [ 18 F]-fluorodeoxyglucose uptake compared with placebo. An explorative analysis indicated a possible effect in persons with history of cardiovascular disease, in line with current guidelines where liraglutide is recommended to patients with history of cardiovascular disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03449654.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circimaging.120.012174

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 18

  1. 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  2. 10.1111/dom.13638 · DOI
  3. 10.1007/s00259-015-3259-3 · DOI · Paper page
  4. 10.1016/S0140-6736(11)61383-4 · DOI · Paper page
  5. 10.1016/j.jcmg.2016.04.007 · DOI
  6. 10.2337/dc12-2082 · DOI
  7. 10.1056/NEJMoa1707914 · DOI · Paper page
  8. 10.1016/j.jacc.2018.03.002 · DOI · Paper page
  9. 10.1016/j.jcmg.2010.01.001 · DOI
  10. 10.1016/j.jacc.2013.04.066 · DOI · Paper page
  11. 10.1016/j.jcmg.2011.08.007 · DOI
  12. 10.1093/eurheartj/ehr077 · DOI · Paper page
  13. 10.1007/s12350-014-9917-1 · doi:10.1007/s12350-014-9917-1
  14. 10.1016/j.jacc.2019.06.057 · DOI
  15. 10.1016/j.jcmg.2011.07.009 · DOI
  16. 10.1007/s00259-015-3259-3 · DOI · Paper page
  17. 10.1016/0735-1097(90)90282-t · DOI · Paper page
  18. 10.1155/2012/904141 · DOI · Paper page

Cited by

See all 53

Metadata

Authors
Ripa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Diaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P., & Kjaer, A.
Venue
Circulation: Cardiovascular Imaging
Published
2021-07
Volume
14
Issue
7
Pages
e012174-e012174
ISSN
  • 1941-9651 (ISSN-L)
  • 1942-0080
OpenAlex
W3173369548
Cited by
53
References
16
FWCI
4.98
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.